Strength of clinical evidence leading to approval of novel cancer medicines in Europe: A systematic review and data synthesis

We aimed to evaluate the quality of clinical evidence that substantiated approval of cancer medicines by the European Medicines Agency (EMA) in the last decade. We performed a systematic review and data synthesis of EMA documents in agreement with PRISMA guidelines. We included the European Public A...

Descripción completa

Detalles Bibliográficos
Autores principales: Farina, Alberto, Moro, Federico, Fasslrinner, Frederick, Sedghi, Annahita, Bromley, Miluska, Siepmann, Timo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262606/
https://www.ncbi.nlm.nih.gov/pubmed/34232554
http://dx.doi.org/10.1002/prp2.816

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262606/
https://www.ncbi.nlm.nih.gov/pubmed/34232554
http://dx.doi.org/10.1002/prp2.816

Ejemplares similares